RXST Healthcare

RxSight, Inc.

$4.59-4.38%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 190.9M USD
Enterprise value: -6.1M USD
Full-time employees: 461

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.16 vs a peer median of 0.63)bigger price swings (beta 1.16 vs peers 0.63)
About average: risk (debt, liquidity and share-price swings)risk

Ranks #857 of 1,157 healthcare companies (bottom 27%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 47% from December 2022 to July 2026.
RxSight had 47% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.RxSight had 47% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.
RxSight's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.RxSight's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.
Stock-based pay is a large cost. Stock pay was 24% of revenue in 2025.
RxSight paid employees $32M in stock in 2025, 24% of its $134M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, RxSight looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

StockQuotient Score

38/ 100

Oct 5 39 → Nov 4 38 (-1)

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-4.2%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-14.2%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield137.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

38/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Revenue growth
▼ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth23.9%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 2.15Sector median: 0.0584 · MAD: 0.0840

Revenue growth-13.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.98Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

25/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-43.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.13Sector median: 0.0706 · MAD: 0.1217

Return on assets-2.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.73Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-17.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.20Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin77.0%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-3.0%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Debt / equity
▲ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.16

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.58Sector median: 0.6250 · MAD: 0.3380

Current ratio4.07×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.07Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.04×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.89Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about RxSight

Is RxSight getting weaker?: Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 38/100 since Oct 28, 2026.
How is RxSight valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -4.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.2% vs peers 1.5% (weaker than 100% of peers).
Is RxSight growing?: More slowly than most of its peers. Growth scores 38/100 against 1,393 healthcare peers. 3-year revenue growth 23.9% vs a peer median of 5.8% (stronger than 84% of peers).3-year revenue growth 23.9% vs peers 5.8% (stronger than 84% of peers). Revenue growth -13.2% vs a peer median of 6.1% (weaker than 86% of peers).Revenue growth -13.2% vs peers 6.1% (weaker than 86% of peers).
How profitable is RxSight?: Less profitable than most of its peers. Profitability scores 25/100 against 1,393 healthcare peers. Operating margin -43.2% vs a peer median of 7.1% (weaker than 83% of peers).Operating margin -43.2% vs peers 7.1% (weaker than 83% of peers).
How risky is RxSight?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 78% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 78% of peers). Beta 1.16 vs a peer median of 0.63 (weaker than 78% of peers).Beta 1.16 vs peers 0.63 (weaker than 78% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	127.5M USD	127.6M USD	+0.1%
Net income (12 months)	−7.7M USD	−8.0M USD	+4.0%
Operating margin	-43.4%	-43.2%	+0.2 pts
Free cash flow (12 months)	−21.6M USD	−27.2M USD	+25.9%
Cash	17.6M USD	13.4M USD	−24.0%
Shares outstanding	41.4M	41.6M	+0.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	20.0%	43.5%	60.4%	70.7%	76.6%	▲ 5.9 pts
Operating margin	-233.6%	-129.2%	-56.2%	-26.3%	-35.8%	▼ 9.5 pts
Net margin	-215.5%	-136.2%	-54.6%	-19.6%	-29.0%	▼ 9.3 pts
Return on assets (ROA)	-25.3%	-44.5%	-26.6%	-8.6%	-12.5%	▼ 3.9 pts
Return on equity (ROE)	-35.2%	-74.3%	-30.3%	-9.8%	-14.1%	▼ 4.4 pts
Free cash flow margin	-206.5%	-125.0%	-52.1%	-16.0%	-14.4%	▲ 1.6 pts
Current ratio	15.92×	7.81×	8.06×	11.36×	10.95×	▼ 3.6%
Quick ratio	15.19×	6.95×	7.22×	10.50×	9.75×	▼ 7.2%
Debt to equity	0.29×	0.45×	0.00×	—	—	—
Interest coverage	-14.34×	-12.80×	-15.14×	-1755.14×	-2536.37×	▼ 45%

RXST price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.16 vs a peer median of 0.63)bigger price swings (beta 1.16 vs peers 0.63)

About average: risk (debt, liquidity and share-price swings)risk

Ranks #857 of 1,157 healthcare companies (bottom 27%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 47% from December 2022 to July 2026.

RxSight had 47% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.RxSight had 47% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.

RxSight's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.RxSight's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.

Stock-based pay is a large cost. Stock pay was 24% of revenue in 2025.

RxSight paid employees $32M in stock in 2025, 24% of its $134M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, RxSight looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Questions investors ask about RxSight

Is RxSight getting weaker?

Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 38/100 since Oct 28, 2026.

How is RxSight valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -4.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.2% vs peers 1.5% (weaker than 100% of peers).

Is RxSight growing?

More slowly than most of its peers. Growth scores 38/100 against 1,393 healthcare peers. 3-year revenue growth 23.9% vs a peer median of 5.8% (stronger than 84% of peers).3-year revenue growth 23.9% vs peers 5.8% (stronger than 84% of peers). Revenue growth -13.2% vs a peer median of 6.1% (weaker than 86% of peers).Revenue growth -13.2% vs peers 6.1% (weaker than 86% of peers).

How profitable is RxSight?

Less profitable than most of its peers. Profitability scores 25/100 against 1,393 healthcare peers. Operating margin -43.2% vs a peer median of 7.1% (weaker than 83% of peers).Operating margin -43.2% vs peers 7.1% (weaker than 83% of peers).

How risky is RxSight?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 78% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 78% of peers). Beta 1.16 vs a peer median of 0.63 (weaker than 78% of peers).Beta 1.16 vs peers 0.63 (weaker than 78% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

127.5M USD

127.6M USD

+0.1%

Net income (12 months)

−7.7M USD

−8.0M USD

+4.0%

Operating margin

-43.4%

-43.2%

+0.2 pts

Free cash flow (12 months)

−21.6M USD

−27.2M USD

+25.9%

Cash

17.6M USD

13.4M USD

−24.0%

Shares outstanding

41.4M

41.6M

+0.5%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

20.0%

43.5%

60.4%

70.7%

76.6%

▲ 5.9 pts

Operating margin

-233.6%

-129.2%

-56.2%

-26.3%

-35.8%

▼ 9.5 pts

Net margin

-215.5%

-136.2%

-54.6%

-19.6%

-29.0%

▼ 9.3 pts

Return on assets (ROA)

-25.3%

-44.5%

-26.6%

-8.6%

-12.5%

▼ 3.9 pts

Return on equity (ROE)

-35.2%

-74.3%

-30.3%

-9.8%

-14.1%

▼ 4.4 pts

Free cash flow margin

-206.5%

-125.0%

-52.1%

-16.0%

-14.4%

▲ 1.6 pts

Current ratio

15.92×

7.81×

8.06×

11.36×

10.95×

▼ 3.6%

Quick ratio

15.19×

6.95×

7.22×

10.50×

9.75×

▼ 7.2%

Debt to equity

0.29×

0.45×

0.00×

—

Interest coverage

-14.34×

-12.80×

-15.14×

-1755.14×

-2536.37×

▼ 45%